Merck Inc.,has announced that it will cease marketing Zontivity (vorapaxar) ,a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of...
Aralez Pharmaceuticals Inc. announced that it acquired the U.S. and Canadian rights to Zontivity (vorapaxar), pursuant to an asset purchase...
The FDA approved Zontivity (vorapaxar) tablets on 8 May 2014 to reduce the risk of heart attack, stroke, cardiovascular death,...
Reviewers for the FDA are giving vorapaxar (Zontivity) from Merck Inc.,, a novel protease-activated receptor 1 (PAR-1) inhibitor that targets...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
The FDA�s Cardiovascular and Renal Drugs Advisory Committee has on 16 January 2014 recommended for approval Zontivity (vorapaxar) from Merck.,....
The FDA has accepted a supplemental new drug application (sNDA) and granted Priority Review for Brilinta (ticagrelor) tablets, from AstraZeneca,...
The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart...
Brilinta (ticagrelor), from AstraZeneca, works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary...